COVID-19 Emergency Medical Supplies Enhancement Act of 2020
This bill expands certain authorities under the Defense Production Act of 1950 and directs the President and federal agencies to take specific actions to support the production of critical medical supplies during the COVID-19 (i.e., coronavirus disease 2019) emergency, including with respect to private-sector coordination, needs assessments, and overall strategies.
[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6858 Introduced in House (IH)]
<DOC>
116th CONGRESS
2d Session
H. R. 6858
To enhance authorities under the Defense Production Act of 1950 to
respond to the COVID-19 emergency, to provide additional oversight of
such authorities, and to require a strategy on securing supply chains
for medical materials, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 13, 2020
Mr. Vargas (for himself, Ms. Waters, Mr. Crow, Mr. Ryan, Mrs. Trahan,
and Ms. Slotkin) introduced the following bill; which was referred to
the Committee on Financial Services, and in addition to the Committee
on Energy and Commerce, for a period to be subsequently determined by
the Speaker, in each case for consideration of such provisions as fall
within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To enhance authorities under the Defense Production Act of 1950 to
respond to the COVID-19 emergency, to provide additional oversight of
such authorities, and to require a strategy on securing supply chains
for medical materials, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``COVID-19 Emergency Medical Supplies
Enhancement Act of 2020''.
SEC. 2. DETERMINATION ON EMERGENCY SUPPLIES AND RELATIONSHIP TO STATE
AND LOCAL EFFORTS.
(a) Determination.--For the purposes of section 101 of the Defense
Production Act of 1950 (50 U.S.C. 4511), the following materials shall
be deemed to be scarce and critical materials essential to the national
defense and otherwise meet the requirements of section 101(b) of such
Act during the COVID-19 emergency period:
(1) Diagnostic tests, including serological tests, for
COVID-19 and the reagents and other materials necessary for
producing or conducting such tests.
(2) Personal protective equipment, including face shields,
N-95 respirator masks, and any other masks determined by the
Secretary of Health and Human Services to be needed to respond
to the COVID-19 pandemic, and the materials to produce such
equipment.
(3) Medical ventilators, the components necessary to make
such ventilators, and medicines needed to use a ventilator as a
treatment for any individual who is hospitalized for COVID-19.
(4) Pharmaceuticals and any medicines determined by the
Food and Drug Administration or another Government agency to be
effective in treating COVID-19 (including vaccines for COVID-
19) and any materials necessary to produce or use such
pharmaceuticals or medicines (including self-injection syringes
or other delivery systems).
(5) Any other medical equipment or supplies determined by
the Secretary of Health and Human Services or the Secretary of
Homeland Security to be scarce and critical materials essential
to the national defense for purposes of section 101 of the
Defense Production Act of 1950 (50 U.S.C. 4511).
(b) Exercise of Title I Authorities in Relation to Contracts by
State and Local Governments.--In exercising authorities under title I
of the Defense Production Act of 1950 (50 U.S.C. 4511 et seq.) during
the COVID-19 emergency period, the President (and any officer or
employee of the United States to which authorities under such title I
have been delegated)--
(1) may exercise the prioritization or allocation authority
provided in such title I to exclude any materials described in
subsection (a) ordered by a State or local government that are
scheduled to be delivered within 15 days of the time at which--
(A) the purchase order or contract by the Federal
Government for such materials is made; or
(B) the materials are otherwise allocated by the
Federal Government under the authorities contained in
such Act; and
(2) shall, within 24 hours of any exercise of the
prioritization or allocation authority provided in such title
I--
(A) notify any State or local government if the
exercise of such authorities would delay the receipt of
such materials ordered by such government; and
(B) take such steps as may be necessary to ensure
that such materials ordered by such government are
delivered in the shortest possible period.
(c) Update to the Federal Acquisition Regulation.--Not later than
15 days after the date of the enactment of this Act, the Federal
Acquisition Regulation shall be revised to reflect the requirements of
subsection (b)(1).
SEC. 3. ENGAGEMENT WITH THE PRIVATE SECTOR.
(a) Sense of Congress.--The Congress--
(1) appreciates the willingness of private companies not
traditionally involved in producing items for the health sector
to volunteer to use their expertise and supply chains to
produce essential medical supplies and equipment;
(2) encourages other manufacturers to review their existing
capacity and to develop capacity to produce essential medical
supplies, medical equipment, and medical treatments to address
the COVID-19 emergency; and
(3) commends and expresses deep appreciation to individual
citizens who have been producing personal protective equipment
and other materials for, in particular, use at hospitals in
their community.
(b) Outreach Representative.--
(1) Designation.--Consistent with the authorities in title
VII of the Defense Production Act of 1950 (50 U.S.C. 4551 et
seq.), the Administrator of the Federal Emergency Management
Agency, in consultation with the Secretary of Health and Human
Services, shall designate or shall appoint, pursuant to section
703 of such Act (50 U.S.C. 4553), an individual to be known as
the ``Outreach Representative''. Such individual shall--
(A) be appointed from among individuals with
substantial experience in the private sector in the
production of medical supplies or equipment; and
(B) act as the Government-wide single point of
contact during the COVID-19 emergency for outreach to
manufacturing companies and their suppliers who may be
interested in producing medical supplies or equipment,
including the materials described under section 2.
(2) Encouraging partnerships.--The Outreach Representative
shall seek to develop partnerships between companies, in
coordination with the Supply Chain Stabilization Task Force or
any overall coordinator appointed by the President to oversee
the response to the COVID-19 emergency, including through the
exercise of the authorities under section 708 of the Defense
Production Act of 1950 (50 U.S.C. 4558).
SEC. 4. ENHANCEMENT OF SUPPLY CHAIN PRODUCTION.
In exercising authority under title III of the Defense Production
Act of 1950 (50 U.S.C. 4531 et seq.) with respect to materials
described in section 2, the President shall seek to ensure that support
is provided to companies that comprise the supply chains for reagents,
components, raw materials, and other materials and items necessary to
produce or use the materials described in section 2.
SEC. 5. OVERSIGHT OF CURRENT ACTIVITY AND NEEDS.
(a) Response to Immediate Needs.--
(1) In general.--Not later than 7 days after the date of
the enactment of this Act, the President, in coordination with
the National Response Coordination Center of the Federal
Emergency Management Agency, the Administrator of the Defense
Logistics Agency, the Secretary of Health and Human Services,
the Secretary of Veterans Affairs, and heads of other Federal
agencies (as appropriate), shall submit to the appropriate
congressional committees a report assessing the immediate needs
described in paragraph (2) to combat the COVID-19 pandemic and
the plan for meeting those immediate needs.
(2) Assessment.--The report required by this subsection
shall include--
(A) an assessment of the needs for medical supplies
or equipment necessary to address the needs of the
population of the United States infected by the virus
SARS-CoV-2 that causes COVID-19 and to prevent an
increase in the incidence of COVID-19 throughout the
United States, including diagnostic tests, serological
tests, medicines that have been approved by the Food
and Drug Administration to treat COVID-19, and
ventilators and medicines needed to employ ventilators;
(B) based on meaningful consultations with relevant
stakeholders, an assessment of the need for personal
protective equipment and other supplies (including
diagnostic tests) required by--
(i) health professionals, health workers,
and hospital staff;
(ii) workers in industries and sectors
described in the ``Advisory Memorandum on
Identification of Essential Critical
Infrastructure Workers during the COVID-19
Response'' issued by the Director of
Cybersecurity and Infrastructure Security
Agency of the Department of Homeland Security
on April 17, 2020 (and any expansion of
industries and sectors included in updates to
such advisory memorandum); and
(iii) other workers determined to be
essential based on such consultation;
(C) an assessment of the quantities of equipment
and supplies in the Strategic National Stockpile
(established under section 319F-2 of the Public Health
Service Act (42 U.S.C. 247d-6b(a)(1))) as of the date
of the report, and the projected gap between the
quantities of equipment and supplies identified as
needed in the assessment under subparagraphs (A) and
(B) and the quantities in the Strategic National
Stockpile;
(D) an identification of the industry sectors and
manufacturers most ready to fulfill purchase orders for
such equipment and supplies (including manufacturers
that may be incentivized) through the exercise of
authority under section 303(e) of the Defense
Production Act of 1950 (50 U.S.C. 4533(e)) to modify,
expand, or improve production processes to manufacture
such equipment and supplies to respond immediately to a
need identified in subparagraph (A) or (B);
(E) an identification of Government-owned and
privately-owned stockpiles of such equipment and
supplies not included in the Strategic National
Stockpile that could be repaired or refurbished;
(F) an identification of previously distributed
critical supplies that can be redistributed based on
current need;
(G) a description of any exercise of the
authorities described under subsection (a)(5) or (b)(1)
of section 2; and
(H) an identification of critical areas of need, by
county and by areas identified by the Indian Health
Service, in the United States and the metrics and
criteria for identification as a critical area.
(3) Plan.--The report required by this subsection shall
include a plan for meeting the immediate needs to combat the
COVID-19 pandemic, including the needs described in paragraph
(1). Such plan shall include--
(A) each contract the Federal Government has
entered into to meet such needs, including the purpose
of each contract, the type and amount of equipment,
supplies, or services to be provided under the
contract, the entity performing such contract, and the
dollar amount of each contract;
(B) each contract that the Federal Government
intends to enter into within 14 days after submission
of such report, including the information described in
subparagraph (A) for each such contract; and
(C) whether any of the contracts described in
subparagraph (A) or (B) have or will have a priority
rating under the Defense Production Act of 1950 (50
U.S.C. 4501 et seq.), including purchase orders
pursuant to Department of Defense Directive 4400.1 (or
any successor directive), subpart A of part 101 of
title 45, Code of Federal Regulations, or any other
applicable authority.
(4) Additional requirements.--The report required by this
subsection, and each update required by paragraph (5), shall
include--
(A) any requests for equipment and supplies from
State or local governments and Indian Tribes, and an
accompanying list of the employers and unions consulted
in developing these requests;
(B) any modeling or formulas used to determine
allocation of equipment and supplies, and any related
chain of command issues on making final decisions on
allocations;
(C) the amount and destination of equipment and
supplies delivered;
(D) an explanation of why any portion of any
contract, whether to replenish the Strategic National
Stockpile or otherwise, will not be filled;
(E) of products procured under this section, the
percentage of such products that are used to replenish
the Strategic National Stockpile, that are targeted to
COVID-19 hotspots, and that are used for the commercial
market;
(F) metrics, formulas, and criteria used to
determine COVID-19 hotspots or areas of critical need
for a State, county, or an area identified by the
Indian Health Service;
(G) production and procurement benchmarks, where
practicable; and
(H) results of the consultation with the relevant
stakeholders required by paragraph (2)(B).
(5) Updates.--The President, in coordination with the
National Response Coordination Center of the Federal Emergency
Management Agency, the Administrator of the Defense Logistics
Agency, the Secretary of Health and Human Services, the
Secretary of Veterans Affairs, and heads of other Federal
agencies (as appropriate), shall update such report every 14
days.
(6) Public availability.--The President shall make the
report required by this subsection and each update required by
paragraph (5) available to the public, including on a
Government website.
(b) Response to Longer-Term Needs.--
(1) In general.--Not later than 14 days after the date of
enactment of this Act, the President, in coordination with the
National Response Coordination Center of the Federal Emergency
Management Agency, the Administrator of the Defense Logistics
Agency, the Secretary of Health and Human Services, the
Secretary of Veterans Affairs, and heads of other Federal
agencies (as appropriate), shall submit to the appropriate
congressional committees a report containing an assessment of
the needs described in paragraph (2) to combat the COVID-19
pandemic and the plan for meeting such needs during the 6-month
period beginning on the date of submission of the report.
(2) Assessment.--The report required by this subsection
shall include--
(A) an assessment of the elements described in
subparagraphs (A) through (E) and subparagraph (H) of
subsection (a)(2); and
(B) an assessment of needs related to COVID-19
vaccines and any additional services to address the
COVID-19 pandemic, including services related to health
surveillance to ensure that the appropriate level of
contact tracing related to detected infections is
available throughout the United States.
(3) Plan.--The report required by this subsection shall
include a plan for meeting the longer-term needs to combat the
COVID-19 pandemic, including the needs described in paragraph
(1). This plan shall include--
(A) a plan to exercise authorities under the
Defense Production Act of 1950 (50 U.S.C. 4501 et seq.)
necessary to increase the production of the medical
equipment, supplies, and services that are essential to
meeting the needs identified in paragraph (2)
(including the number of N-95 respirator masks and
other personal protective equipment needed), based on
meaningful consultations with relevant stakeholders--
(i) by the private sector to resume
economic activity; and
(ii) by the public and nonprofit sectors to
significantly increase their activities;
(B) results of the consultations with the relevant
stakeholders required by subparagraph (A)(ii);
(C) an estimate of the funding and other measures
necessary to rapidly expand manufacturing production
capacity for such equipment and supplies, including--
(i) any efforts to expand, retool, or
reconfigure production lines;
(ii) any efforts to establish new
production lines through the purchase and
installation of new equipment; or
(iii) the issuance of additional contracts,
purchase orders, purchase guarantees, or other
similar measures;
(D) each contract the Federal Government has
entered into to meet such needs or expand such
production, the purpose of each contract, the type and
amount of equipment, supplies, or services to be
provided under the contract, the entity performing such
contract, and the dollar amount of each contract;
(E) each contract that the Federal Government
intends to enter into within 14 days after submission
of such report, including the information described in
subparagraph (D) for each such contract;
(F) whether any of the contracts described in
subparagraph (D) or (E) have or will have a priority
rating under the Defense Production Act of 1950 (50
U.S.C. 4501 et seq.), including purchase orders
pursuant to Department of Defense Directive 4400.1 (or
any successor directive), subpart A of part 101 of
title 45, Code of Federal Regulations, or any other
applicable authority; and
(G) the manner in which the Defense Production Act
of 1950 (50 U.S.C. 4501 et seq.) could be used to
increase services necessary to combat the COVID-19
pandemic, including services described in paragraph
(2)(B).
(4) Updates.--The President, in coordination with the
National Response Coordination Center of the Federal Emergency
Management Agency, the Administrator of the Defense Logistics
Agency, the Secretary of Health and Human Services, the
Secretary of Veterans Affairs, and heads of other Federal
agencies (as appropriate), shall update such report every 14
days.
(5) Public availability.--The President shall make the
report required by this subsection and each update required by
paragraph (4) available to the public, including on a
Government website.
(c) Report on Exercising Authorities Under the Defense Production
Act of 1950.--
(1) In general.--Not later than 14 days after the date of
the enactment of this Act, the President, in consultation with
the Administrator of the Federal Emergency Management Agency,
the Secretary of Defense, and the Secretary of Health and Human
Services, shall submit to the appropriate congressional
committees a report on the exercise of authorities under titles
I, III, and VII of the Defense Production Act of 1950 (50
U.S.C. 4501 et seq.) prior to the date of such report.
(2) Contents.--The report required under paragraph (1) and
each update required under paragraph (3) shall include, with
respect to each exercise of such authority--
(A) an explanation of the purpose of the applicable
contract, purchase order, or other exercise of
authority (including an allocation of materials,
services, and facilities under section 101(a)(2) of the
Defense Production Act of 1950 (50 U.S.C. 4511(a)(2)));
(B) the cost of such exercise of authority; and
(C) if applicable--
(i) the amount of goods that were purchased
or allocated;
(ii) an identification of the entity
awarded a contract or purchase order or that
was the subject of the exercise of authority;
and
(iii) an identification of any entity that
had shipments delayed by the exercise of any
authority under the Defense Production Act of
1950 (50 U.S.C. 4501 et seq.).
(3) Updates.--The President shall update the report
required under paragraph (1) every 14 days.
(4) Public availability.--The President shall make the
report required by this subsection and each update required by
paragraph (3) available to the public, including on a
Government website.
(d) Quarterly Reporting.--The President shall submit to Congress,
and make available to the public (including on a Government website), a
quarterly report detailing all expenditures made pursuant to titles I,
III, and VII of the Defense Production Act of 1950 (50 U.S.C. 4501 et
seq.).
(e) Sunset.--The requirements of this section shall terminate on
the later of--
(1) December 31, 2021; or
(2) the end of the COVID-19 emergency period.
SEC. 6. ENHANCEMENTS TO THE DEFENSE PRODUCTION ACT OF 1950.
(a) Health Emergency Authority.--Section 107 of the Defense
Production Act of 1950 (50 U.S.C. 4517) is amended by adding at the end
the following:
``(c) Health Emergency Authority.--With respect to a public health
emergency declaration by the Secretary of Health and Human Services
under section 319 of the Public Health Service Act, or preparations for
such a health emergency, the Secretary of Health and Human Services and
the Administrator of the Federal Emergency Management Agency are
authorized to carry out the authorities provided under this section to
the same extent as the President.''.
(b) Emphasis on Business Concerns Owned by Women, Minorities,
Veterans, and Native Americans.--Section 108 of the Defense Production
Act of 1950 (50 U.S.C. 4518) is amended--
(1) in the heading, by striking ``modernization of small
business suppliers'' and inserting ``small business
participation and fair inclusion'';
(2) by amending subsection (a) to read as follows:
``(a) Participation and Inclusion.--
``(1) In general.--In providing any assistance under this
Act, the President shall accord a strong preference for
subcontractors and suppliers that are--
``(A) small business concerns; or
``(B) businesses of any size owned by women,
minorities, veterans, and the disabled.
``(2) Special consideration.--To the maximum extent
practicable, the President shall accord the preference
described under paragraph (1) to small business concerns and
businesses described in paragraph (1)(B) that are located in
areas of high unemployment or areas that have demonstrated a
continuing pattern of economic decline, as identified by the
Secretary of Labor.''; and
(3) by adding at the end the following:
``(c) Minority Defined.--In this section, the term `minority'--
``(1) has the meaning given the term in section 308(b) of
the Financial Institutions Reform, Recovery, and Enforcement
Act of 1989; and
``(2) includes any indigenous person in the United States,
including any territories of the United States.''.
(c) Additional Information in Annual Report.--Section 304(f)(3) of
the Defense Production Act of 1950 (50 U.S.C. 4534(f)(3)) is amended by
striking ``year.'' and inserting ``year, including the percentage of
contracts awarded using Fund amounts to each of the groups described in
section 108(a)(1)(B) (and, with respect to minorities, disaggregated by
ethnic group), and the percentage of the total amount expended during
such fiscal year on such contracts.''.
(d) Definition of National Defense.--Section 702(14) of the Defense
Production Act of 1950 is amended by striking ``and critical
infrastructure protection and restoration'' and inserting ``, critical
infrastructure protection and restoration, and health emergency
preparedness and response activities''.
SEC. 7. SECURING ESSENTIAL MEDICAL MATERIALS.
(a) Statement of Policy.--Section 2(b) of the Defense Production
Act of 1950 (50 U.S.C. 4502) is amended--
(1) by redesignating paragraphs (3) through (8) as
paragraphs (4) through (9), respectively; and
(2) by inserting after paragraph (2) the following:
``(3) authorities under this Act should be used when
appropriate to ensure the availability of medical materials
essential to national defense, including through measures
designed to secure the drug supply chain, and taking into
consideration the importance of United States competitiveness,
scientific leadership and cooperation, and innovative
capacity;''.
(b) Strengthening Domestic Capability.--Section 107 of the Defense
Production Act of 1950 (50 U.S.C. 4517) is amended--
(1) in subsection (a), by inserting ``(including medical
materials)'' after ``materials''; and
(2) in subsection (b)(1), by inserting ``(including medical
materials such as drugs to diagnose, cure, mitigate, treat, or
prevent disease that essential to national defense)'' after
``essential materials''.
(c) Strategy on Securing Supply Chains for Medical Articles.--Title
I of the Defense Production Act of 1950 (50 U.S.C. 4511 et seq.) is
amended by adding at the end the following:
``SEC. 109. STRATEGY ON SECURING SUPPLY CHAINS FOR MEDICAL MATERIALS.
``(a) In General.--Not later than 180 days after the date of the
enactment of this section, the President, in consultation with the
Secretary of Health and Human Services, the Secretary of Commerce, the
Secretary of Homeland Security, and the Secretary of Defense, shall
transmit a strategy to the appropriate Members of Congress that
includes the following:
``(1) A detailed plan to use the authorities under this
title and title III, or any other provision of law, to ensure
the supply of medical materials (including drugs to diagnose,
cure, mitigate, treat, or prevent disease) essential to
national defense, to the extent necessary for the purposes of
this Act.
``(2) An analysis of vulnerabilities to existing supply
chains for such medical articles, and recommendations to
address the vulnerabilities.
``(3) Measures to be undertaken by the President to
diversify such supply chains, as appropriate and as required
for national defense.
``(4) A discussion of--
``(A) any significant effects resulting from the
plan and measures described in this subsection on the
production, cost, or distribution of vaccines or any
other drugs (as defined under section 201 of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321));
``(B) a timeline to ensure that essential
components of the supply chain for medical materials
are not under the exclusive control of a foreign
government in a manner that the President determines
could threaten the national defense of the United
States; and
``(C) efforts to mitigate any risks resulting from
the plan and measures described in this subsection to
United States competitiveness, scientific leadership,
and innovative capacity, including efforts to cooperate
and proactively engage with United States allies.
``(b) Progress Report.--Following submission of the strategy under
subsection (a), the President shall submit to the appropriate Members
of Congress an annual progress report evaluating the implementation of
the strategy, and may include updates to the strategy as appropriate.
The strategy and progress reports shall be submitted in unclassified
form but may contain a classified annex.
``(c) Appropriate Members of Congress.--The term `appropriate
Members of Congress' means the Speaker, majority leader, and minority
leader of the House of Representatives, the majority leader and
minority leader of the Senate, the Chairman and Ranking Member of the
Committees on Armed Services and Financial Services of the House of
Representatives, and the Chairman and Ranking Member of the Committees
on Armed Services and Banking, Housing, and Urban Affairs of the
Senate.''.
SEC. 8. GAO REPORT.
(a) In General.--Not later than 270 days after the date of the
enactment of this Act, and annually thereafter, the Comptroller General
of the United States shall submit to the appropriate congressional
committees a report on ensuring that the United States Government has
access to the medical supplies and equipment necessary to respond to
future pandemics and public health emergencies, including
recommendations with respect to how to ensure that the United States
supply chain for diagnostic tests (including serological tests),
personal protective equipment, vaccines, and therapies is better
equipped to respond to emergencies, including through the use of funds
in the Defense Production Act Fund under section 304 of the Defense
Production Act of 1950 (50 U.S.C. 4534) to address shortages in that
supply chain.
(b) Review of Assessment and Plan.--
(1) In general.--Not later than 30 days after each of the
submission of the reports described in subsections (a) and (b)
of section 5, the Comptroller General of the United States
shall submit to the appropriate congressional committees an
assessment of such reports, including identifying any gaps and
providing any recommendations regarding the subject matter in
such reports.
(2) Monthly review.--Not later than a month after the
submission of the assessment under paragraph (1), and monthly
thereafter, the Comptroller General shall issue a report to the
appropriate congressional committees with respect to any
updates to the reports described in subsections (a) and (b) of
section 5 that were issued during the previous 1-month period,
containing an assessment of such updates, including identifying
any gaps and providing any recommendations regarding the
subject matter in such updates.
SEC. 9. DEFINITIONS.
In this Act:
(1) Appropriate congressional committees.--The term
``appropriate congressional committees'' means the Committees
on Appropriations, Armed Services, Energy and Commerce,
Financial Services, Homeland Security, and Veterans' Affairs of
the House of Representatives and the Committees on
Appropriations, Armed Services, Banking, Housing, and Urban
Affairs, Health, Education, Labor, and Pensions, Homeland
Security and Governmental Affairs, and Veterans' Affairs of the
Senate.
(2) COVID-19 emergency period.--The term ``COVID-19
emergency period'' means the period beginning on the date of
enactment of this Act and ending after the end of the incident
period for the emergency declared on March 13, 2020, by the
President under Section 501 of the Robert T. Stafford Disaster
Relief and Emergency Assistance Act (42 U.S.C. 4121 et seq.)
relating to the Coronavirus Disease 2019 (COVID-19) pandemic.
(3) Relevant stakeholder.--The term ``relevant
stakeholder'' means--
(A) representative private sector entities;
(B) representatives of the nonprofit sector; and
(C) representatives of labor organizations
representing workers, including unions that represent
health workers, manufacturers, public sector employees,
and service sector workers.
(4) State.--The term ``State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, and any territory or possession of the United States.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Financial Services, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Financial Services, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line